Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small nuclear ribonucleoprotein polypeptide F (SNRPF) is a highly conserved protein encoded by the SNRPF gene. It acts as a core component of the spliceosomal small nuclear ribonucleoproteins (snRNPs), specifically U1, U2, U4, and U5 snRNPs, which are essential building blocks for the spliceosome complex involved in pre-mRNA splicing. SNRPF participates in both the major and minor (U12-type) spliceosomes, mediating the correct processing of pre-mRNA in the nucleus, and is also involved in histone 3'-end processing as part of the U7 snRNP. It is found predominantly in the nucleus and cytosol. Although SNRPF is critical for cell viability, there are currently no known therapeutic drugs that directly target this protein, and it is not regarded as a primary therapeutic target (such as a receptor, enzyme, or transporter)[1][2][4][6][7]. However, its dysregulation is associated with certain diseases, most notably spinal muscular atrophy, and it has been identified as a biomarker for nasopharynx carcinoma[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small nuclear ribonucleoprotein polypeptide F (SNRPF).